
Opinion|Videos|December 13, 2024
Role of Step-Up Dosing
Panelists discuss how this patient was admitted after the day 1 dose of talquetamab for observation for CRS and ICANS. Patients such as this are given a 0.01-mg/kg dose on the first day, a 0.06-mg/kg dose on day 3, and a 0.04-mg/kg dose on day 5 if there are no issues. The patient is then monitored for 48 hours and is discharged before getting the 0.08-mg/kg dose.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Can you describe the dosing regimen for talquetamab, both as an inpatient and outpatient?
- Please highlight why we decreased dosing frequency and what the data are telling us to do now?
- Given the toxicity associated with talquetamab, can you describe the conversations with the patients when giving the first dose of talquetamab?
Advertisement
Related to this article

A complete response letter was given to ivonescimab for patients with previously treated EGFR-mutated NSCLC.

Matthew Karr, DO, highlights advances in the CLL paradigm, current goals in researching CNS lymphoma, and other future directions in hematology/oncology.

Ralph V. Boccia, MD, FACP, discussed educating hospital teams and using tocilizumab to manage bispecific toxicities when patients need admission.

Martin Gleave, CM, MD, FRCSC, FACS, explained how the GUNS trial is using tumor genomics to guide neoadjuvant therapy in high-risk prostate cancer.

Daniel Y.C. Heng, MD, MPH, FRCPC, explained how subsequent therapy and durable responses may have shaped overall survival results in LITESPARK-011.

Ralph V. Boccia, MD, FACP, noted how designated hospitals and a 24/7 on-call team support emergencies during bispecific step-up dosing.

Arturo Loaiza-Bonilla, MD, MSEd, FACP, co-founder of Massive Bio and system-wide chief of hematology and oncology at St. Luke’s, explains how AI is matching patients to clinical trials, where the technology falls short, and why he left academia to build what oncology was missing.
Advertisement
Advertisement
Trending on CancerNetwork
1
Matching Neoadjuvant Therapy to Tumor Genomics in High-Risk Prostate Cancer
2
Partnering With Local Hospitals to Manage CRS and ICANS From Bispecific Antibodies
3
FDA Provides CRL to Ivonescimab/Chemotherapy for Pretreated EGFR+ NSCLC
4
FDA Approves Perioperative Durvalumab/Enfortumab Vedotin in MIBC
5


